The genetic defect-Adenosine Deaminase (ADA) deficiency may be cured permanently by:
periodic infusion of genetically engineered lymphocytes having functional ADA cDNA
administering adenosine deaminase activators
introducing bone marrow cells producing ADA into cells at early embryonic stages
invitro cell culture therapy
treatments like bone marrow transplantation and enzyme replacement therapy are not completely curative. Gene therapy involving the infusion of genetically engineered lymphocytes requires periodic infusion because these cells are not immortal. However, if the gene isolated from marrow cells producing ADA is introduced into cells at early embryonic stages, it could be a permanent cure .
Join thousands of students and practice with AI-generated mock tests.